Following two decades at Kendall, Tyco Healthcare and Covidien, Richard Meelia rides off into the sunset at COV.
Richard Meelia, the CEO who led Covidien plc (NYSE:COV) in its various incarnations for more than two decades will hand over the keys to the corner officer to José (Joe) Almeida today without fanfare.
Meelia, 62, was named president & CEO of Covidien in June 2007, after it was spun out of the disintegrating Tyco International. He was elected chairman in October 2008 and has been with the company in its different forms for 20 years.
Meelia was also president at Kendall Healthcare Products Co., which was spun into Tyco Healthcare and then Covidien, growing the business from $600 million to more than $10.4 billion in 2010.
Meelia will stay on as non-executive chairman of Covidien's board for a transition period of up to a year after his retirement, according to a press release
In a statement sent to MassDevice Meelia said he had every confidence in his successor.
"Joe Almeida is a great leader who has proven his mettle over many years, most recently in his outstanding direction of our Medical Devices segment," he said. "As I prepare to transition my responsibilities to Joe, I have every confidence that, backed by our superb global workforce, he will lead our Company on to even better performance and greater success in the years to come."
Shares of Smith & Nephew are up today on solid 3rd-quarter results, including 6% growth for its U...
Here's a look at some of the top Wall Street stories for medical device companies this week:...
Abiomed says it's come to an agreement with the FDA on an indication for its flagship Impella 2.5...
Medtronic and Covidien say their pending, $43 billion merger is expected to close in early 2015.